Gilead Prices Cystic Fibrosis Drug Cayston At Slight Premium To Competitor
Gilead Sciences will price its cystic fibrosis drug Cayston at an 8 percent premium to its competitor, Novartis' TOBI (tobramycin)
Gilead Sciences will price its cystic fibrosis drug Cayston at an 8 percent premium to its competitor, Novartis' TOBI (tobramycin)